The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I certainly don’t, his story changes like the wind
In regards to Align, its a trick one to understand the reasoning, it could be a few reasons, 1. Non payment of a bill, but with so many shared it wouldn’t make sense, 2. Inaccurate information in research, it could be that they are trying to clean up there act and that the information on Barracuda, DBI etc has caused them to lose credibility (not that they have any imho)
There will be loads of reasons, maybe they have had bad experiences with new members of the board etc
lol, you believe robertsham’s posts??
Robertsham admitted that he was shorting ADMe at 12,500K a point. That is he was shorting 1,250,000 shares in ADME on 20/10/2021 which represents .8% of the entire share capital of the company on one shorter alone. I don’t see any shorts disclosed over this period so its clearly in breach of the law not reporting this amount of shorts.
How many more of TW crew are shorting ADME and not disclosing it. ADme should contact the FCA and investigate TW and his band of shorters for non disclosure.
"On 6 January 2021, the Treasury published the Short Selling (Notification Thresholds) Regulations 2021 No. 5 (the Regulations) to amend the notification threshold under Article 5(2) of the Short Selling Regulation from 0.2% to 0.1% of the issued share capital of an issuer. This change comes into force on 1 February 2021.
This means that from 1 February 2021 the notification threshold for issued share capital of a company that has shares admitted to trading on a UK trading venue (UK Regulated Market and UK MTF) is 0.1%."
Its clear Robertsham breached the shorting threshold by a margin of 800%
RobertSham
RE: Big Sell20 Oct 2021 11:33
My short was £12.5k pp at 2.32p. Will hold till 1 and under.
1. where is the evidence that there are any significant short positions
against ADME shares? … there is no such evidence that i can see, but
happy to read any relevant links / declarations etc. ginksy can provide.
2. assuming for the moment that align have *not* done anything illegal /contrary
to their own regulatory requirements, why on earth would they stop covering
ADME just because someone else had moaned to the FCA about ADME &/or the
nomad &/or align? …granted, align’s marketing communications (- they hardly
merit the term, ‘research’ imv! - ) have been laughably wide of the mark re
forecasts for s/price etc, but it is not a regulatory offence for a PR/marketing
company like align to publish a wildly over-optimistic share price forecast.
both these issues just seem to be attempts to over-complicate a much more
straightforward situation; (a) ADME’s share price has performed very badly
because the company has performed very badly, including v poor comms
with its shareholders and the market, and (b) imho align have probably
stopped coverage simply because ADME have stopped paying them; that
would hardly be surprising as align’s input doesn’t seem to have helped
keep the price up. there might be a myriad other reasons possible (e.g.
align seeking to avoid reputational damage from continued association
with ADME, or vice versa), but Occam’s razor suggests simplest explanation
is simply that ADME aren’t paying align to promote their shares anymore.
this is classic AIM chatboard stuff, when a useless AIM tiddler is failing, up come
posters making excuses about TW, market-makers, manipulation, blackrock,
evil shorters, etc etc … anything to try to deflect blame from the company itself.
This is the bull they tried a few weeks back ... complaining to the regulator on adme ,the nomad cairn and brokers Ardern....
They were probably laughed at by the regulator so now they are complaining about Align... hopeing they might get align to sell their shares to create liquidity so that they can close their shorts.
" By Tom Winnifrith, the Crook of AIM | Sunday 28 November 2021.... I have written to the Oxymorons at AIM Regulation,led by the bogus Sheriff of AIM Marcus Stuttard, following Fake Sheikh expose on this website which should mean a 7 AM Monday Suspension of Trading in shares in ADM Energy (ADME) and a full enquiry into Nomad Cairn Financial & broker Ardern. "
Whats not to understand. Tw and his crew have probably complained to the regulators over aligns research on adme . The same way they have pestered the regulators on adme . they'll try anything to get people to sell so that they can close their shorts.
Ginksy, the Cease All coverage of ADME is on the Align Research Website ? I do not understand your post
TW and his gang of shorters/throlls must be harassing align now to say align suddenly dropped their coverage of adme. they must be stuck with big open shorts in adme and no liquidity to close them.
i see that align still have a glowing testimonial from osa on their website.
so if you trust osa’s good judgement, honesty & business acumen, maybe
you would also want to trust osa’s reportedly positive view on align. (lol.)
perhaps dr green would care to post some explanation about
why his previous views & stance re ADME should be “disregarded”.
? what does he think has changed about the company?
( ?or is it just that ADME now refuse to pay up?)
I got a message form LSE to say the following;
Please refrain from posting incorrect information. We've been informed Dr Michael Green still works for Align. Thanks.
they are a small company who take payments (often in the form of shares)
from AIM companies to do PR work to try to promote those shares to pis.
- that often takes the form of write-ups predicting fabulously future high
share prices for those companies, and purporting to offer some ‘research’
into the business. but also align sometimes tweet about the companies
that they are paid to promote, and post on chat sites such as lse. my own
personal view about their supposed ‘research’ is that it’s usually very poor
quality & unrealistic, but of course that’s a matter of opinion. it’s unarguable,
however, that it clearly should not be relied on as ‘independent’ research,
since their client companies pay them to produce it, & align will therefore
usually also own shares in the company that they are trying to promote.
if one believes the RNS history for ADME, then align were, and still are,
a big holder of shares in this company, while the price has been cratering.
(their holding is large enough that if they had sold any since a previous
RNS in may 2020, then that change should have been RNS’d to the market.)
Who are Align?
my post about align was removed very quickly. so i suspect they do
still have at least some of their holding and are still hoping for a better
exit opportunity, and they are still watching this chatboard. probably
not coincidental they issued that tweet disavowing all their previous
statements about this company after pedro reminded people about
align’s previous ludicrous share price target & their large holding that
was RNSd (with no subsequent TR1 update to say that they’d sold any).
Coincidentally Align issued a tweet today;
Cessation of Coverage on ADME. All prior forecasts and stance to be disregarded.
You win some you lose some eh!
I'm highly sceptical of all Align buy recommendations now.
RNS on 18th Nov 2020 states Align held a 12.05% interest up from 11%.
There is no subsequent RNS on any disposal.
? maybe he sobered up?
In May 2020 Align Research initiated a Conviction Buy on ADME with a 19.21p target.
There is 25 page PDF available with lots of detail on Aje and OML with oil that sells at premium to BRENT.
The research note is credited to an analyst Dr Michael Green, has anyone heard from him since?